Vir Biotechnology, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| VIR | BHVN | ASMB | VOR | 2137.HK | BINV.ST | |
|---|---|---|---|---|---|---|
| Market cap | 1.99B | 2.30B | 404.57M | 1.24B | 739.58M | 246.77M |
| P/E (TTM) | — | — | 19.1 | 0.1 | — | — |
| Forward P/E | -4.8 | -8.2 | -7.7 | -5.7 | -2.0 | -1.0 |
| Price/book | 2.1 | -23.4 | 1.3 | -9.0 | 0.3 | 1.2 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +129.88% | +78.66% | −36.33% | −5.02% | −44.59% | −88.73% |
| Today | +4.90% | −2.37% | −0.25% | +1.31% | 0.00% | +4.60% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All VIR news ›Vir Biotechnology (VIR) director More disposed of 16,000 shares
Plus members following VIR got this by push and email at 14:30:46 ET - 0.5s after publication. Robert J More (director at Vir Biotechnology Inc., VIR) reported that they disposed of 16,000 shares on Aug 11, 2026. After these transactions…
Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer
Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to VIR-5500, a PSMA-targeted PRO-XTEN® dual-masked T-cell engager (TCE), for the treatment of late-line…
Vir Biotechnology to Participate in the Jefferies 2026 London Healthcare Conference
Vir CEO Marianne De Backer to present at Jefferies London Healthcare Conference on Nov 18, webcast at investors.vir.bio. Plus members following VIR got this by push and email at 16:05:03 ET - 3.5s after publication. Vir Biotechnology's…
News from Virax BioLabs Group Limited A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.
news News from Virax BioLabs Group Limited A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Oct 29, 2026,…
Vor Bio Down on Q3 Results
Vor Bio (NASDAQ: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today reported financial results for the third quarter ended September 30, 2026, and provided a corporate update. “We ended…
Vir Biotechnology: A Big Pharma Collaboration And 2 Clinical Catalysts This Quarter
Vir Biotechnology is approaching multiple clinical readouts from drugs with positive data previously. Click here to read an analysis of VIR stock now. - VIR's PRO-XTEN platform has attracted major pharma collaborations, validating its…
Vor Bio initiated with an Outperform at William Blair
William Blair initiated coverage of Vor Bio (VOR) with an Outperform rating and $58.82 fair value estimate. Vor is a biotechnology company focus... Vor Bio initiated with an Outperform at William Blair William Blair initiated coverage of…
Vir Biotechnology, Inc. (VIR) – What Are Investment Firms Thinking About This Stock?
Posted by Defense World Staff on Oct 25th, 2026 Check Out Our Latest Analysis on Vir Biotechnology Shares of VIR opened at $10.57 on Friday. Vir Biotechnology has a fifty-two week low of $4.82 and a fifty-two week high of $12.00. The firm…
Vir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal
Vir Biotechnology said on Wednesday it had signed a collaboration agreement worth up to $1.88 billion with Gilead Sciences to discover and develop new cancer treatments for solid tumors. ... Vir, Gilead team up on solid tumor cancer…
Gilead, Vir Biotechnology Sign USD 1.88 Billion Deal to Develop Cancer Treatments
Bengaluru: Vir Biotechnology said on Wednesday it had signed a collaboration agreement worth up to USD 1.88 billion with Gilead Sciences to discover and develop new cancer treatments for solid tumors. Shares of Vir rose more than 10% in…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- quantisnow.com14
- stocktitan.net7
- defenseworld.net3
- biospace.com2
- pharmexec.com2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 44 articles, not a forecast.